Long Term Immunogenicity up to 15 Years After the First Booster Immunization With GSK Biologicals' Encepur Adults (Polygeline-free Tick-Borne Encephalitis Vaccine for Adults) in Adults Who Received 1 of 3 Different Primary Vaccination Schedules

Trial Profile

Long Term Immunogenicity up to 15 Years After the First Booster Immunization With GSK Biologicals' Encepur Adults (Polygeline-free Tick-Borne Encephalitis Vaccine for Adults) in Adults Who Received 1 of 3 Different Primary Vaccination Schedules

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs Tick-borne encephalitis vaccine (Primary)
  • Indications Encephalitis
  • Focus Pharmacodynamics
  • Acronyms TBEV POLYGELINE FREE-025 EXT:021
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 15 Jan 2018 Planned End Date changed from 7 Apr 2022 to 3 Nov 2021.
    • 15 Jan 2018 Planned primary completion date changed from 7 Apr 2022 to 3 Nov 2021.
    • 13 Nov 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top